Related Experiment Video
Updated: Jun 8, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways
Fereshteh Asgharzadeh1, Maryam Moradi Binabaj2, Sahar Fanoudi3
1Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
Insights
Lipid-based nanoparticles (LNPs) show promise for improving drug delivery in liver cancer (hepatocellular carcinoma, HCC) treatment. This review explores LNPs
Area of Science:
- Oncology and Nanomedicine: Focus on hepatocellular carcinoma (HCC) and therapeutic drug delivery systems.
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited survival rates.
- Current HCC treatments face challenges due to impaired drug delivery in the diseased liver.
- Lipid-based nanoparticles (LNPs) offer a potential solution for enhanced drug targeting and efficacy.
Purpose of the Study:
- To review the current applications of lipid-based nanoparticles (LNPs) in developing anti-HCC therapies.
- To highlight the potential of LNPs in overcoming drug delivery barriers in liver cancer.
- To identify future directions and advancements in LNP-based HCC treatment.
Main Methods:
- Comprehensive literature review of existing research on LNPs for HCC therapy.
- Analysis of LNP structural properties and their impact on drug delivery.
- Examination of diverse therapeutic cargos and their compatibility with LNPs.
Main Results:
- LNPs demonstrate versatile structural configurations for improved physical stability.
- LNPs can accommodate various therapeutic agents with different properties.
- Existing research indicates significant potential for LNPs in anti-HCC drug development.
Conclusions:
- Lipid-based nanoparticles represent a promising platform for advancing hepatocellular carcinoma treatment.
- Further research into LNP applications could overcome critical drug delivery challenges in HCC.
- LNPs offer a pathway to improved therapeutic outcomes for liver cancer patients.
